Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doxil and Carboplatin in Metastatic Breast Cancer
NCT00303108Phase 2Completed
- Sponsor
- US Oncology Network
- Start
- Dec 2005
- Primary completion
- Mar 2010
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pegylated liposomal doxorubicin in breast cancer, sponsored by US Oncology Network. Primary endpoint: Objective Response Rate up to 54 months. Started Dec 2005; status: completed.
02
Drugs
pegylated liposomal doxorubicin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00303108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00303108.